Please login to the form below

Not currently logged in
Email:
Password:

Merck Serono/ Domain Parkinson's deal

Merck Serono and Domain Therapeutics are to partner in a deal to develop drugs to target neurodegenerative diseases such as Parkinson's

Merck Serono - Merck's biopharmaceutical division - and Domain Therapeutics are to partner in a deal to develop drugs to target neurodegenerative diseases such as Parkinson's disease.

The agreement will see France-based biopharmaceutical company, Domain, offer Merck access to a portfolio of optimised investigational compounds. In return, Domain will receive €2m in an upfront payment, with up to €132m available in milestone payments for the first two products to be developed.

The compounds to be developed are positive allosteric modulators for metabotropic glutamate receptor 4 (mGluR4). Glutamate receptors are a member of the G-protein coupled receptor (GPCR) family, a group of proteins which transmit signals into cells, and are seen as therapeutic targets for Parkinson's disease.

"We are pleased to have the opportunity to work with Domain Therapeutics, which has developed great expertise in the GPCR area," said Bernhard Kirschbaum, executive vice president for global research and development at Merck Serono. "This partnership with Domain Therapeutics reflects our long-term commitment to develop new treatments for neurodegenerative diseases."

Pascal Neuville, CEO, Domain Therapeutics, said: "This agreement is a validation of Domain Therapeutics' business model of addressing difficult GPCRs and partnering compounds, with a significant deal, at an early stage of development."

17th January 2011

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
AMICULUM Limited

AMICULUM® is an independent global healthcare communications, consulting and learning business with a global team of >220 healthcare communications professionals,...

Latest intelligence

Are you ready for the digital health revolution?
In this edition of Delta magazine, we explore how rapid digitalization has transformed the care pathway and reveal how life science companies can succeed in the digital age....
#DemandDiversity: Can new medical publication guidelines help fix diversity in clinical trials?
Over the last 8 months, JAMA have been working on a new set of guidelines for research papers looking to publish with them, which is summarised in their latest editorial...
DATA shutterstock_1818502577-640.jpg
Empowering patients empowers results
Patient-centricity is key when it comes to creating a more flexible, efficient and modern process for clinical trials...

Infographics